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We identified three novel mutations (p.Gly39Arg, p.Lys157Glu, p.Cys379Gly) and one previously known mutation
(p.Asp141Asn) in the von Willebrand factor propeptide from three von Willebrand disease patients. All four
mutations impaired multimerization of von Willebrand factor, due to reduced oxidoreductase activity of isomeric
propeptide. These mutations resulted in the endothelial reticulum retention and impaired basal and stimulated
secretions of von Willebrand factor. Our results support that the mutations in the D1 domain lead to defective
multimerization, intracellular trafficking, and secretion of von Willebrand factor and result in bleeding of patients.
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Von Willebrand factor propeptide (VWFpp), composed
of D1 and D2 domains, is necessary for the multimeriza-
tion, intracellular trafficking, and secretion of the factor
[1–3]. Few mutations in the D1 domain of VWFpp have
been reported, and the pathogenic nature of these muta-
tions remains largely unknown [4, 5].
We found three novel mutations (p.Gly39Arg,
p.Lys157Glu, p.Cys379Gly) and one previously known
mutation (p.Asp141Asn) in the VWFpp from three von
Willebrand disease (VWD) patients (Additional file 1).
The proband 1 (P1) and proband 2 (P2) were type 3
VWD, while the proband 3 (P3) was type 1 VWD [6].
The laboratory results of these patients and their family
members are summarized in Table 1. P1 and P2 pre-
sented undetectable von Willebrand factor (VWF) multi-
mer, and P3 exhibited light multimer pattern, compared
to normal plasma (NP) (Additional file 2: Figure S1). All
mutations are located in the D1 domain of VWFpp.* Correspondence: cshcma@medmail.com.cn
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creativecommons.org/publicdomain/zero/1.0/To determine whether and how these mutations im-
pair VWF expression and function, we transiently trans-
fected the human embryonic kidney 293 cells (HEK293)
with wild type (WT) or VWF mutant constructs and an-
alyzed VWF multimer (Fig. 1a,b). In the supernatant, the
WT-VWF showed a full range of multimers similar to
NP. Asp141Asn, Lys157Glu, and Cys379Gly mutants
each exhibited different degrees of the loss of large-
and medium-sized multimers. We also co-transfected
Asp141Asn and Gly39Arg mutants and found that a
partial VWF protein multimerization was readily
detectable. When mutant and WT-VWF were co-
transfected into HEK293 cells, the abnormal VWF multi-
mers were all restored (Additional file 3: Figure S2). We
examined cell lysates for VWF multimer and found that
multimerization from all VWF mutations were inhibited
in different levels as showed in the media. To determine
the underlying mechanisms of defective VWF multimeri-
zation, we employed a previously established dimerization
model using D1D2D′D3 fragment of VWF [7, 8]. In this
model, the decreased dimerization of D1D2D′D3 indicates
the reduced oxidoreductase of mutant VWFpp. Under the
non-reducing condition (Fig. 1c), truncated WT (T-WT)
VWF formed both D′D3 monomers and dimers in thee distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Phenotypic and genetic features of three unrelated VWD families
Family Members VWF mutation Genotype APTT ratio PT ratio TT ratio VWF: Ag VWF: RCo FVIII: C BS
(sec) (sec) (sec) (IU/dL) (IU/dL) (IU/dL)
F1 Proband P1 G39R D141N Compound heterozygous 2.24 1.07 0.97 1.0 2.3 2.0 6
F1 Father P1F D141N Heterozygous 1.09 1.15 1.24 48.4 50.2 73.5 0
F1 Mother P1M G39R Heterozygous 1.12 1.05 0.91 30.3 36.4 50.6 1
F2 Proband P2 K157E C1165R Compound heterozygous 1.95 1.04 0.89 3.0 2.1 3.0 6
F2 Father P2F K157E Heterozygous 0.94 1.02 0.98 87.2 80.3 97.8 1
F3 Proband P3 C379G Heterozygous 1.50 1.17 1.07 8.0 5.9 13.1 9
F3 Brother P3B C379G Heterozygous 1.21 1.00 0.90 14.3 13.6 25.3 3
Normal range – – – 0.82–1.18 0.86–1.14 0.80–1.20 50–160 50–120 50–150 0–3 or 0–5a
PT prothrombin time, APTT activated partial thromboplastin time, TT thrombin time, VWF:Ag, von Willebrand antigen, VWF:RCo von Willebrand factor ristocetin
cofactor activity, FVIII:C factor VIII coagulant activity, BS bleeding scores
a0–3 in male, 0–5 in female
Fig. 1 Defective multimerization of mutant VWF and reduced dimerization of mutant truncated VWF. a HEK293 cells were transiently transfected
by equal WT or mutant full-length VWF plasmid. Seventy hours after transfection, the supernatant of cells were collected for multimer analysis. In
order to detect whether the mutations have abnormal multimer pattern, we measured equal VWF antigen of the mutations, wild type, and NP.
Lane 1 is the negative control of the mimic empty vector. Lanes 2–6 show the supernatant obtained from VWF mutant transfections and indicate
decreases in high to medium-sized multimers to varying degrees. Exclusively, dimers formed with the Gly39Arg mutant (lane 2). The ability to
form multimers was partly recovered by co-transfection of Gly39Arg and Asp141Asn (lane 4). b In the lysates of transfected cells, a similar
decrease in the formation of VWF multimers was seen in the variants. However, WT-VWF exhibited a multimer pattern as observed for normal
plasma. c HEK293 cells were transiently transfected by equal WT or mutant truncated VWF. In the media of transfected cells, dimerizations of
truncated recombinant VWF were detected by Western blotting under the non-reducing condition. Lane 1 shows the empty pSecTag2/Hygro B
vector. Dimers were absent in the Gly39Arg mutant (lane 2) while lanes 3–6 tapered in the dimer to different degrees. d In the supernatant of
the transfected cells, the truncated VWF mutations and WT D1D2D′D3 fragment were examined under the reducing condition, and only D′D3
monomers were found
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Gly39Arg, T-Asp141Asn, T-Lys157Glu, and T-Cys379Gly)
were reduced, compared to that observed with T-WT. Co-
transfection of the T-Gly39Arg and T-Asp141Asn resulted in
a modest restoration of dimer formation compared to the
single transfection of truncated Gly39Arg. This result
indicates that the impaired multimerization is caused
by decreased oxidoreductase activity of the isomeric
propeptide. Under the reducing condition (Fig. 1d), D′
D3 dimers were reduced to D′D3 monomers in both
mutant and wild type D1D2D′D3 fragment.
The VWF antigen was measured in the conditioned
media and cell lysates of the transiently transfected
HEK293 cells (Additional file 4: Figure S3). The expres-
sions of mutant Gly39Arg or Asp141Asn in the super-
natant were significantly impaired, at the level of 2.8 ±
0.3 % to 2.5 ± 0.1 % of the WT. However, the expres-
sions of mutant Lys157Glu or Cys379Gly product in the
supernatant were less severely decreased at the levels of
26.0 ± 4.1 % and 22.4 ± 3.8 % of the WT. In co-Fig. 2 Mutant VWF is retained in the ER. a HEK293 cells were transfected w
(green channel, left panel). PDsRed2-ER Vector was also co-transfected into c
scale bar is 10 μm. The right panel shows the merged confocal images of the
percentage of total VWF in cells (n = 3 independent experiments). All values a
HEK293 cells were transiently transfected with WT or mutant full-length VWF,
vector control is shown in lane 1. The bands of pro-VWF are predominant in t
pro-VWF and mature VWF in the lysate of WT, and lane 7 shows only maturetransfection of Gly39Arg and Asp141Asn constructs,
only 2.6 ± 0.1 % VWF was detectable in the supernatant,
implying that both mutants do not mutually rescue each
other from their defects. We also co-transfected the WT
and each mutant (Gly39Arg, Asp141Asn, Lys157Glu, or
Cys379Gly), and 59.3 ± 4.3 %, 57.3 ± 8.9 %, 86.6 ± 7.1 %,
or 33.9 ± 1.2 % of WT were detected, respectively. This
suggests that four mutants can be partially restored by
the WT. In the cell lysates of single or co-transfected
variants, the VWF levels did not changed dramatically.
We found that the level of VWF antigen in the super-
natant of HEK-293 cells expressing WT-VWF increased
by 2.28-fold after phorbol 12-myristate-13-acetate (PMA)
stimulation. However, cells expressing four mutations ex-
hibited no significant changes in VWF antigen secretion
upon PMA stimulation (Additional file 5: Figure S4).
By immunofluorescent staining of VWF proteins
(Fig. 2a), we found that VWF formed green granules in
cells. Only 37.8 ± 9.3 % WT-VWF was observed in the
endoplasmic reticulum (ER), while 74.8 ± 2.5 % Gly39Arg,ith plasmids expressing WT or mutant VWF and then stained for VWF
ells to delineate the endoplasmic reticulum (middle panel, red). The
first two panels. b Bar graph represents VWF and the ER overlapping as a
re mean ± SD. ***p < 0.001 compared to WT (one-way ANOVA). c After
cell lysates were reduced and analyzed by Western blotting. The empty
he lysates of VWF mutant variants (lanes 2–5). Lane 6 shows both
VWF in normal plasma
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74.3 ± 1.8 % Cys379Gly mutants were detected in the ER
(Fig. 2b). In the cell lysates, the bands of pro-VWF were
predominant, and mature VWF was hardly detectable in
the cells expressing Gly39Arg, Asp141Asn, Lys157Glu,
and Cys379Gly, compared to that of WT-VWF (Fig. 2c).
These results indicate that the mutant VWF are retained
in the ER and fail to be transported to the Golgi, resulting
in the decreased VWF secretion.
In summary, four mutations in the D1 domain of
VWF impair the multimerization of VWF by directly
downregulating the oxidoreductase of the propeptide,
disrupt the transport of VWF from the ER to the Golgi,
and inhibit the basal and regulated secretion of VWF.
These defects contribute to the quantitative loss of
VWF, leading to the bleeding diathesis of VWD patients.Additional files
Additional file 1: Supplementary data. Detailed methods and
materials are shown.
Additional file 2: Figure S1. Plasma VWF multimers in three unrelated
VWD patients and their family members. (A) Plasma samples were
assessed by 1.3 % SDS-agarose gel electrophoresis and Western blotting,
and the image was taken after exposure for 3 min. Normal plasma (NP)
was shown in lane 4, 7 and 10 as a positive control. VWF multimer
structures were absent in lane 1 (P1) and lane 5 (P2), while P3 and P3B
presented very light multimer bands. (B) The image was taken after
6-minute exposure. VWF multimer patterns of P3 and P3B were normal
while those of P1 and P2 were still absent. (C) Schematic diagram of
VWF. Arrows indicate the locations of four mutations in the D1 domain
on the whole pro-VWF.
Additional file 3: Figure S2. Restored VWF multimerization of
co-expression of mutant and WT-VWF. HEK293 cells were transiently
transfected by WT and mutant full-length VWF plasmid in ratio of 1:1.
VWF multimers present normal pattern in all co-expression of mutant
and WT-VWF, compared to that observed with WT-VWF.
Additional file 4: Figure S3. Decreased basal secretion of mutant
rVWF. HEK293 cells were transiently transfected by equal WT or mutant
full-length VWF plasmid in single transfection. In co-transfection, two
plasmids were transfected in ratio of 1:1, and added up to the equivalent
plasmid of single transfection. VWF levels were determined in conditioned
media and cell lysates from HEK293 cells transfected with single expressing
vector or co-expressing vectors in duplicate. Each bar represents the average
values of three separate transfections. VWF levels were measured by ELISA
and are shown as percentages relative to WT-VWF in media or lysates. The
left side of the short vertical line represents single-transfections while the
right side represents co-transfections.
Additional file 5: Figure S4. Decreased regulated secretion of mutant
rVWF. Forty-eight hours post-transfection, HEK293 cells were rinsed and
changed to release media with or without PMA (control). After further 60
min incubation, VWF levels were determined by ELISA in the release
media and cell lysates. Each bar represents VWF secretion in the medium
as a percentage of total VWF (medium plus lysate). Error bars indicate
standard deviation of triplicate samples. The numbers above the bars indicate
the fold increase of stimulated release compared with the control samples.Abbreviations
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